Drugs / PLX2853
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03787498 | Mar 2019 → Jun 2021 | acute myeloid leukemia, myelodysplastic syndrome | Opna Bio LLC | Completed | No outcome recorded |
| Phase 1 | NCT03297424 | Sep 2017 → Jun 2021 | diffuse large B-cell lymphoma, follicular lymphoma, ovarian clear cell adenocarcinoma, small cell lung carcinoma +1 | Opna Bio LLC | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05677373 | Jan 2023 → Jul 2025 | uveal melanoma | Alliance for Clinical Trials in Oncology | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04556617 | Sep 2020 → May 2022 | castration-resistant prostate carcinoma | Opna Bio LLC | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04493619 | Aug 2020 → Apr 2022 | malignant epithelial tumor of ovary | Opna Bio LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLX2853 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04493619 ↗ |
| Action | Inhibit | “PLX2853 works by targeting and inhibiting certain activities within cells that promote tumor growth” NCT05677373 ↗ |
| Route | Oral | “Patients receive PLX2853 orally (PO) in combination with trametinib PO throughout the study” NCT05677373 ↗ |
| Target | BRD4 | “combination BRD4 inhibitor PLX2853” NCT05677373 ↗ |